Advicenne Reports 2023 Gross Sales1 up 20% to €4.43 Million

Regulatory News:

Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces today 2023 gross sales¹ of €4.4 million, up 20% compared to the previous year (2022: €3,7 million).

In 2023, in line with the Company's strategic plan, most of the growth in gross sales came from Sibnayal, its lead product. These are up 84% in volume over the full year compared with 2022. In value terms, Sibnayal gross sales rose by 40% over the same period to €1.94 million (vs. €1.39 million in 2022). The difference between growth in value and volume is largely due the growing portion of total sales generated by the commercial partnerships outside France and the transfer prices’ structure.

Gross sales of Likozam and Levidcen reached €1.87 and €0.62 million respectively. Overall, gross sales for the Neurology franchise (Likozam and Levidcen) rose by more than 8% over the period.

Gross sales (€ millions)	2023	2022	Growth
Sibnayal	1.94	1.39	+40%
Neurology of which Likozam of which Levidcen	2.49 1.87 0.62	2.31 1.70 0.60	+8% +10% +3%
Total	4.43	3.69	+20%

Didier Laurens, Chief Executive Officer of Advicenne, commented: "The year 2023 marked the start of Advicenne's commercial roll-out. Despite a regulatory environment that remains complex in terms of pricing and reimbursement, we are particularly satisfied with the progress of Sibnayal sales. This is particularly the case in France, where the deployment of a sales force has led to a record acceleration in sales over several consecutive months. On the other hand, the situation is more mixed in the United Kingdom, which has been penalized by a pharmaceutical market difficult environment. At the same time, our partnerships in other European countries and in the Middle East are continuing to be set up, with good performances recorded in certain zones. We remain as focused as ever on our mission to meet unmet medical needs in rare diseases, with treatments that improve the daily lives of patients and their families".